Cagrilintide NEW

Product Function:

Cagrilintide is a novel long-acting acylated amylin analogue under development as a non-selective amylin receptor (AMYR) and calcitonin G-protein-coupled receptor (CTR) agonist.

Cagrilintide results in significant weight loss and reduced food intake.

Cagrilintide has potential in obesity research.

Cagrilintide is under development for the treatment of obesity and type 2 diabetes. The drug candidate is administered as a once-daily and once-weekly subcutaneous formulation. It is a long-acting amylin analogue. Amylin is co-located with insu in secretory granules and co-secreted with insu by pancreatic beta cells in response to food intake.

Application

Weight loss 

Anti-diabetes

Alzheimer's disease

an amylin/calcitonin receptor agonist, administered once a week, with weight loss effects, developed in combination with . The combination, which contains cagrilintide 2.4 mg and 2.4 mg, is administered once weekly and has shown potential for glucose-lowering and weight loss in a Phase 2 study.